AzTrials
AzTrials

Adolescent DrinkingNCT05597865

Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents

A study testing Economic Empowerment Intervention and Alcohol and Drug Use Risk Reduction Sessions in people with Adolescent Drinking and HIV/AIDS, run by Washington University School of Medicine at 1 site in Uganda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The proposed study will test the impact of an economic empowerment intervention on reducing alcohol and drug use (ADU) among adolescents and youth living with HIV (AYLHIV) in poverty-impacted communities in Uganda. Read more about this study

Who is it for?
Ages 18 to 24 yearsHealthy volunteers can take part
Conditions the study is for
Adolescent Drinking, HIV/AIDS, Drug Use
What is being tested?
Economic Empowerment Intervention and Alcohol and Drug Use Risk Reduction Sessions
Could I receive a placebo?
No, everyone receives an active treatment
How many people
95 participants
Where
1 siteUganda
Study dates
12 Oct 2023to 6 Jun 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 24 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • male or female AYLHIV aged 15-24 years;
  • medically diagnosed with HIV and aware of their HIV status;
  • enrolled in care at one of the selected HIV clinics.
  • positive self-report or urine test for alcohol or drug use

Who cannot join

  • any AYLHIV with negative urine alcohol or drug use test and negative self-report for alcohol and drug use
  • anyone with a significant cognitive impairment that interferes with their understanding of the informed consent process, or is unable/unwilling to consent.

Trial locations and contacts

1 site in 1 country.

Uganda1 site
  • International Center for Child Health and Development Field Office

    Masaka

Other trials in Uganda

About this study

The proposed study will test the impact of an economic empowerment intervention on reducing alcohol and drug use (ADU) among adolescents and youth living with HIV (AYLHIV) in poverty-impacted communities in Uganda. It focuses on improving understanding of multi-level context- specific risk and protective factors for ADU among AYLHIV.

Read the detailed description

Adolescent alcohol and drug use (ADU) is a significant public health challenge in sub-Saharan Africa (SSA). About 41.6% of adolescents in SSA reported using at least one psychoactive agent, with alcohol being the most commonly used drug. Uganda, one of the poorest countries in SSA, has the second highest rate of per capita alcohol consumption in SSA (15.1 liters of pure alcohol vs regional average of 6.2 liters of pure alcohol) and one third of Ugandan adolescents have used alcohol in their lifetime, 22.5 million are current drinkers, and over 50% engage in heavy episodic drinking. These estimates reach even greater magnitudes in the country's fishing villages - a key vulnerable population- where ADU is normative. A few studies have assessed ADU among AYLHIV, yet AYLHIV are at higher risk for ADU, and ADU impedes adherence to antiretroviral therapy (ART) retention in care, and viral suppression. Several studies have examined the risk and resilience factors for ADU but few interventions targeting ADU have been tested in SSA. . The majority of ADU interventions have been implemented in school settings, which may exclude adolescents in fishing communities that have high rates of school dropout. Moreover, none has targeted risk factors such as poverty and mental health, which are rampant among AYLHIV and their families, undermine AYLHIV's coping skills and resources, and have been associated with increased risk for ADU among adolescents. Economic empowerment (EE) interventions have the potential to prevent ADU among AYLHIV by reducing poverty and its associated mental health impacts, and also bolstering AYLHIV and their families' resources to overcome the challenges associated with HIV. Given the lack of evidence-based culturally tailored interventions to prevent ADU in AYLHIV in low-income settings such as Uganda, this study proposes to: Aim 1a. Examine the prevalence and consequences of ADU in a sample of 200 AYLHIV (ages 18-24) seen at six (6) HIV clinics located in the fishing communities of southwestern Uganda. ADU will be measured using self-report and biological data (i.e. urine). Aim 1b. Using a mixed methods approach, identify the multi-level (individual, interpersonal, community and structural) factors associated with ADU among AYLHIV. Aim 2: Using a subset of the sample, explore the feasibility and short-term effects of a EE intervention on ADU among AYLHIV. Our intervention focuses on older adolescents and young adults in a high-risk environment (i.e. fishing communities) to elucidate the contextually relevant risk and resilience factors for ADU among AYLHIV undergoing social transitions. Additionally we innovatively target the most commonly occurring risk and resilience factors for ADU (i.e. poverty and mental health problems) through the EE that includes provision of youth development savings accounts, financial literacy sessions and ADU risk reduction sessions.

Being tested
Economic Empowerment Intervention, Alcohol and Drug Use Risk Reduction Sessions
Medical subject headings
Underage Drinking, Acquired Immunodeficiency Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Economic Empowerment InterventionBehavioural

    Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts

  • Alcohol and Drug Use Risk Reduction SessionsBehavioural

    All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.

Study groups in NCT05597865
Study groupRoleWhat they receive
Control ArmOtherControl arm will received Alcohol and Drug Use Risk Reduction Sessions
Receives: Behavioral: Alcohol and Drug Use Risk Reduction Sessions
InterventionExperimentalParticipants in the intervention arm will receive four (4) Financial Literacy (FL) training sessions and receive a Youth Development Savings account (YDA) at a financial institution accredited by the Bank of Uganda for long-term savings. Each YDA account will be opened in the name of the participant. Savings will be matched at a 1:1 rate with money from the program.
Receives: Behavioral: Economic Empowerment Intervention; Behavioral: Alcohol and Drug Use Risk Reduction Sessions

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Completing the Study at 6 Months

    Percentage of participants completing the study at 6 months

    Measured: Baseline and 6 months

  2. Number of Participants Enrolling in the Study at Baseline

    Number of participants enrolling in the study at baseline

    Measured: Baseline

Secondary outcomes (16)
  1. Percentage of Participants That Self-reported Use of Any Drug in the Last 3 Months at the Baseline Assessment

    Percentage of participants that self-reported use of any drug in last 3 months at the baseline assessment . Any of the drugs in the list of substances specified in the NIDA-Modified ASSIST questionnaire.

    Measured: baseline

  2. Percentage of Participants That Self-reported Use of Any Drug in Last 3 Months at the 6-month Assessment

    Percentage of participants that self-reported use of any drug in last 3 months at the 6-month assessment. Any of the drugs in the list of substances specified in the NIDA-Modified ASSIST questionnaire.

    Measured: 6 month follow-up

  3. Optimism Scale Total Score at Baseline

    Optimism scale measures hope that something good is going to happen in the future. Total score ranges from 9 to 45. Items were rated on a 5-item scale with higher scores are indicative of higher levels of optimism.

    Measured: Baseline

  4. Optimism Scale Total Score at 6 Months

    Optimism scale measures hope that something good is going to happen in the future. Total score ranges from 9 to 45. Items were rated on a 5-item scale with higher scores are indicative of higher levels of optimism.

    Measured: 6 months

  5. Beck Hopelessness Scale Total Score at Baseline

    Beck Hopelessness Scale total score at baseline is a 20-item scale that assesses negative expectations about the future. The total score ranges from 0-20. Higher scores indicate greater levels of hopelessness (more negative expectations about the future, less motivation, more pessimism.

    Measured: Baseline

  6. Beck Hopelessness Scale Total Score at 6 Months

    Beck Hopelessness Scale total score at baseline is a 20-item scale that assesses negative expectations about the future. The total score ranges from 0-20. Higher scores indicate greater levels of hopelessness (more negative expectations about the future, less motivation, more pessimism.

    Measured: 6 months

  7. Depressive Symptoms Total Score at Baseline

    Center for Epidemiological Studies Depression Scale (CES-D). Total score range from 0-60. Higher scores indicate greater severity of depressive symptoms.

    Measured: baseline

  8. Depressive Symptom Total Score at 6 Months

    Center for Epidemiological Studies Depression Scale (CES-D). Total score range from 0-60. Higher scores indicate greater severity of depressive symptoms.

    Measured: 6 months

  9. Percentage of Participants That Self-reported Use of Any Drug in Last 12 Months at the Baseline Assessment

    Percentage of participants that self-reported use of any drug in last 12 months at the baseline assessment. Any of the drugs in the list of substances specified in the NIDA-Modified ASSIST questionnaire.

    Measured: baseline

  10. Percentage of Participants That Self-reported Use of Any Drug in Last 12 Months at 6 Month Assessment

    Percentage of participants that self-reported use of any drug in last 12 months at the 6-month assessment. Any of the drugs in the list of substances specified in the NIDA-Modified ASSIST questionnaire.

    Measured: 6 month follow-up

  11. Percentage of Participants That Self-reported Use of Alcohol in Last 12 Months at Baseline

    Percentage of participants that self-reported use of alcohol in the last 12 months at the baseline assessment.

    Measured: baseline

  12. Percentage of Participants That Self-reported Use of Alcohol in Last 12 Months at the 6-month Assessment

    Percentage of participants that self-reported use of alcohol in the last 12 months at the 6-month assessment.

    Measured: 6-month follow-up

  13. Percentage of Participants With a Positive Urine Test for Any Drug at Baseline

    Percentage of participants with a positive urine test for any drug at the baseline assessment

    Measured: baseline

  14. Percentage of Participants With a Positive Urine Test for Any Drug at the 6-month Assessment

    Percentage of participants with a positive urine test for any drug at the 6-month assessment

    Measured: 6 month follow-up

  15. Percentage of Participants With a Positive Urine Test for Alcohol at the Baseline Assessment

    Percentage of participants with a positive urine test for alcohol at the baseline assessment

    Measured: baseline

  16. Percentage of Participants With a Positive Urine Test for Alcohol at the 6-month Assessment

    Percentage of participants with a positive urine test for alcohol at the 6-month assessment

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 2022
  2. Study start12 Oct 2023
  3. Primary completion6 Jun 2024
  4. Study completion6 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
95 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05597865
Sponsor's protocol ID
1R21AA030225-01
Other IDs
1R21AA030225-01
Status last verified
Nov 2025
First submitted
20 Oct 2022
Last updated
2 Dec 2025
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified participant data will be made available to other researchers through the NIH central data repositories upon request from the researcher. The researcher will be required to provide a research question, hypothesis, and analysis plan and strategies for maintaining data integrity in order to access the data.

Publications

  • Brathwaite R, Mutumba M, Nanteza J, Filiatreau LM, Migadde H, Namatovu P, Nabisere B, Mugisha J, Mwebembezi A, Ssewamala FM. Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2023 Jun 14;12:e46486. doi: 10.2196/46486.

    PubMed 37314844

Questions about this trial

What is this clinical trial studying?

A study testing Economic Empowerment Intervention and Alcohol and Drug Use Risk Reduction Sessions in people with Adolescent Drinking and HIV/AIDS, run by Washington University School of Medicine at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Dec 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Completing the Study at 6 Months (time frame: Baseline and 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05597865, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in